NPWT Evidence Library
NPWT Evidence Library › Topics › Safety and harms

Safety and harms

NPWT safety, harms and adverse events

80 sources

Bleeding over vascular repairs and grafts, retained foam, device-related adverse events, and the harm figures that belong in a consent discussion. Collects what this library knows about how NPWT goes wrong.

All 80 sourcesReferences (RIS)Spreadsheet (CSV)

Evidence in one minute

Best-established harms

  • Skin blisters under closed-incision NPWT: RR 3.55 in the Cochrane review (Norman 2022), the best-corroborated harm.
  • Device intolerance (pump noise, tubing, pain): 12 of 183 vs 0 of 194 after aortic surgery, very low certainty (Cristino 2025).
  • Itching or redness in 36%, and pain on removal in 12%, of closed-incision users, resolving once the dressing came off (Baker 2024).

Serious but less common

  • Bleeding over an arterial repair: 4 of 69 (5.8%) where a two-layer protective protocol was used, at a median of day 18; seven of the nine bleeds in the series occurred with infection (Sivash 2025).
  • Retained foam: the true rate is unknown. It is found 1 month to 5 years later, and foam does not show on X-ray (Anagnostakos 2021).
  • Pyoderma gangrenosum: debridement and negative pressure can make it worse (pathergy) (Lehnert 2026).

Prevention

  • Count foam pieces in and out at every change, as swabs are counted, and record them.
  • Protect a vascular repair or graft with a non-adherent layer, keep the pressure low over vessels, and control infection.
  • Watch for fresh blood in the tubing, a sudden change in output, an unexplained fall in haemoglobin, or loss of seal.

Do not use when

  • Pyoderma gangrenosum is suspected: an absolute contraindication in this library.
  • The wound worsens under NPWT and cultures are negative: stop rather than escalate.

Harms register

43 entries from 31 sources tagged to this page: each harm, how often it happened and where the figure comes from.

What happenedWith NPWTComparatorEffect (95% CI)Source
Death
All-cause mortality: NPWT against Bogotá bag (1 trial)5/20 (25.0%)7/20 (35.0%)RR 0.71 (0.27 to 1.88)Cheng 2022
Meta-analysis / SR
All-cause mortality, established deep sternal wound infection (34 retrospective cohorts, era-confounded)
allocation by clinician, institution or era; no confounding adjustment
——RR 0.46 (0.35 to 0.61); 34 trialsLiu 2024
Meta-analysis / SR
All-cause mortality, obese or diabetic cardiac surgery patients (Prevena periods against standard dressing)
OR 0.79 (0.52 to 1.20) as printed; cluster cross-over, not powered
39/1022 (3.8%)57/1208 (4.7%)RR 0.81 (0.54 to 1.20)Scheier 2025
RCT
In-hospital death (modified ITT: one early death per arm excluded)0/83 (0.0%)1/82 (1.2%)RR 0.33 (0.01 to 7.97)Älgå 2020
RCT
Mortality, whole trial (3 of the 4 deaths in the ABThera arm)4/34 (11.8%)——Auer 2021
RCT
In-hospital death, Fournier's gangrene (retrospective; printed p<0.05 does not reproduce, Fisher 0.17)
adjusted OR 0.42 (0.18 to 0.95) on 19 events and 5 covariates
10/64 (15.6%)9/31 (29.0%)RR 0.54 (0.24 to 1.19)Dogan 2026
Cohort / comparative
30-day mortality, sternal NPWT2/176 (1.1%)——Sjögren 2010
Case series
Serious Deaths reported to the FDA with NPWT, 2007 to February 2011 (no denominator; most at home or in long-term care)12 reports——US 2011
HTA / regulatory
Bleeding
Serious Bleeding leading to transfusion, conflict-related extremity wounds32/81 (39.5%)24/78 (30.8%)RR 1.28 (0.84 to 1.97)Älgå 2020
RCT
30-day coded bleeding, insured US children given NPWT (claims data)19/3184 (0.6%) children——Santosa 2019
Cohort / comparative
Serious Major bleeding (Yellin definition), sternal NPWT6/176 (3.4%)——Sjögren 2010
Case series
Bleeding episodes, children with burns under NPWT
upper 95% bound 11.7%
0/29 (0.0%) children——Ren 2017
Case series
Serious Tibial artery erosion and haemorrhage on day 17 of NPWT (case report)1 report——White 2005
Case report
Serious Of those deaths, the ones with bleeding (vascular grafts, sternal and groin wounds, anticoagulation)9 reports——US 2011
HTA / regulatory
Providers who had seen bleeding with NPWT (FDA survey, 342 web respondents)22% of respondents——Kaufman-Rivi 2013
Survey / qualitative
Fistula
Serious Fistula: NPWT against Bogotá bag (1 trial)2/20 (10.0%)1/20 (5.0%)RR 2.00 (0.20 to 20.33)Cheng 2022
Meta-analysis / SR
Serious Enteric fistula: ABThera against Suprasorb CNP (both NPWT; ABThera in the NPWT column)4/17 (23.5%)0/17 (0.0%)RR 9.00 (0.52 to 155.24)Auer 2021
RCT
Intestinal fistulation after NPWT (secondary figure quoted from Rao)6/29 (20.7%)——Li 2014
Review / background
Ischaemia or tissue damage
Skin necrosis, closed incisions (fewer with NPWT)——RR 0.38 (0.18 to 0.80)Patel 2026
Meta-analysis / SR
Serious Right ventricular rupture during NPWT for deep sternal wound infection
one per 522 NPWT-days
4/176 (2.3%)——Sjögren 2010
Case series
Serious Right ventricular rupture under VAC after sternotomy (multi-institution case series; no denominator)5 reports——Sartipy 2006
Case series
Serious Right ventricular rupture after 24 h at −120 mmHg over an unprotected heart, against a rigid barrier (porcine model)
Pressure −120 mmHg
3/8 (37.5%) animals0/8 (0.0%)RR 7.00 (0.42 to 116.91)Lindstedt 2011
Mechanism / in-vitro
Skin injury (blisters, maceration, dermatitis)
Skin blistering, closed incisions (85 RCTs; abstract figures)
NNH 18 as printed; full text not read
——RR 4.51 (2.37 to 8.58)Patel 2026
Meta-analysis / SR
Skin allergy under NPWT alone, pressure ulcers7/45 (15.6%)——Tian 2024
Cohort / comparative
Pain
Pain on dressing removal, gauze-filled NPWT at −80 mmHg (no comparator; sponsor-authored)
Pressure −80 mmHg
none at 80% of removals dressings——Hurd 2010
Case series
Pain or discomfort reported by inpatients on NPWT (qualitative interviews; 6 of 17 needed medication)12/17 (70.6%)——Miyanaga 2022
Survey / qualitative
Providers who had seen pain at dressing change (same survey)29% of respondents——Kaufman-Rivi 2013
Survey / qualitative
Retained foam or dressing
Serious Retained foam pieces in FDA injury reports, 2007 to 200932 reports——Hayes 2016
HTA / regulatory
Serious Retained foam causing persistent infection; found 1 month to 5 years later and not seen on X-rayrate unknown (9 case reports and series)——Anagnostakos 2021
Review / background
Serious Foam accidentally left in the wound, of 24 MAUDE reports in the first half of 20068 reports——Medical 2006
HTA / regulatory
Device problems
Device-related adverse events, closed incisions (85 RCTs; abstract figures)
NNH 11 as printed
——RR 11.87 (4.74 to 29.74)Patel 2026
Meta-analysis / SR
Device malfunction under closed-incision NPWT after panniculectomy (single-surgeon series)
malfunction carried OR 3.3 (1.04 to 10.45) for any complication
16/91 (17.6%)——Patel 2020
Case series
Pressure outside the usual range
Adverse events at −75 against −125 mmHg (1 trial)
Pressure −75 vs −125 mmHg; Certainty Very low
——RR 1.50 (0.28 to 8.04); 1 trial, 40 patientsLiu 2018
Meta-analysis / SR
A trial run at −600 mmHg (Buttenschön 2001), excluded by IQWiG; its pain rate was linked speculatively to the pressure
Pressure −600 mmHg (−80 kPa)
1 trial——Institute 2006
HTA / regulatory
Fall in hand perfusion under a circumferential dressing, −400 against −125 mmHg (healthy volunteers, Cape Town)
Pressure −400 vs −125 mmHg; no hand showed increased perfusion; same dataset as the Kairinos 2011 thesis
40% vs 17% fall (both p < 0.0005) limbs——Kairinos 2009
Mechanism / in-vitro
Perineal vacuum-sealing drainage run at −200 to −400 mmHg with continuous saline and intermittent hydrogen peroxide (no other source supports either)
Pressure −200 to −400 mmHg
the whole NPWT arm——Li 2025
Cohort / comparative
Transcutaneous oxygen under the foam at −125 mmHg fell by 84% to 6 mmHg in every diabetic foot tested
Pressure −125 mmHg
21/21 (100.0%) feet——Jung 2016
Case series
Pressures used in maxillofacial and deep-neck vacuum-sealing drainage, with no safety data at these levels
Pressure −300 to −450 mmHg (4 studies); −125 to −150 mmHg (1); one printed pressure value impossible
4 of 6 studies above −300 mmHg——Freundlich 2026
Review / background
Other harms
Cancer recurrence under NPWT after resection (6 observational studies)
reassurance on 267 patients, not proof of safety
11/118 (9.3%)17/149 (11.4%)RR 0.82 (0.40 to 1.68)Wang 2022
Meta-analysis / SR
Adverse events, post-operative diabetic foot wounds (1 trial)
Certainty Very low
——RR 0.96 (0.72 to 1.28); 1 trial, 162 patientsLiu 2018
Meta-analysis / SR
Treatment-related adverse events, diabetic foot (3–4 RCTs)——RR 1.12 (0.66 to 1.89); 3 trialsLiu 2017
Meta-analysis / SR
Injury reports to the FDA with NPWT, same period174 reports——US 2011
HTA / regulatory
Adverse events with NPWT reported to the FDA (MAUDE), January 2000 to June 2006more than 100 reports——Medical 2006
HTA / regulatory

Counts are as printed in each source; percentages and risk ratios are computed from the counts here. A source with no comparator shows a rate only, and a regulator report has no denominator, so it is a signal, not a rate. How the register is built.

Key studies

Meta-analysis / SRGRADE ⊕⊕⊕◯ Moderate2022Supports NPWT

The authoritative source for closed-incision NPWT

Negative pressure wound therapy for surgical wounds healing by primary closure (Cochrane Review) — Norman G, Shi C, Goh EL, Murphy EMA, Reid A, Chiverton L, et al · Cochrane Database Syst Rev
What it found
OutcomeEstimateCertainty
SSIRR 0.73 (95% CI 0.63–0.85), I² 29%; 8.7% vs 11.75%; 44 studies, 11,403 participantsModerate
DehiscenceRR 0.97 (95% CI 0.82–1.16), I² 4%; 23 studies, 8,724 participantsModerate — probably no difference
MortalityRR 0.78 (95% CI 0.47–1.30), I² 0%; 11 studies, 6,384 participantsLow
ReoperationRR 1.13 (95% CI 0.91–1.41) — point estimate favours standard dressing; 18 trials, 6,272Low
SeromaRR 0.82 (95% CI 0.65–1.05), I² 0%; 15 trials, 5,436Low
Skin blistersRR 3.55 (95% CI 1.43–8.77), I² 74%; 11 trials, 5,015 — more blistering with NPWT, and the interval excludes no effectLow
HaematomaRR 0.79 (95% CI 0.48–1.30), I² 0%; 17 trials, 5,909Very low
PainLittle to no difference; measures disparateLow

Cost-effectiveness (six economic studies, five indications including — new in pub7 — vascular surgery with inguinal incisions): results differ by indication. Moderate-certainty evidence that NPWT in surgery for lower limb fracture was not cost-effective at any willingness-to-pay threshold, and that it probably is cost-effective in obese women undergoing caesarean section. Other indications: low or very low certainty.

Limitations
  • The full text on file is the superseded pub5. pub7's figures here come from its published abstract. If a claim turns on a subgroup, an individual trial, or a risk-of-bias judgement in pub7, obtain the pub7 full text first.
  • A further update may exist. Cochrane versions continue; check for a .pub8 before citing.
  • Most included trials had unclear or high risk of bias in at least one key domain, which is why SSI is Moderate and not High.
  • Blister heterogeneity is high (I² 74%) and the certainty is Low — state the signal, do not overstate its precision.
  • Pools across orthopaedic, obstetric, vascular and general surgery; for a vascular-groin claim the population-specific syntheses (Svensson-Björk 2019, Sexton 2020) remain the direct evidence, with this review establishing the general principle.
  • The review notes a large number of ongoing studies whose results may change its findings.
Appraisal and reference

CAT: OCEBM 1 · The review applies GRADE itself and this appraisal adopts its per-outcome ratings rather than substituting a global one, because that is the whole point of a review that grades each outcome separately. SSI: Moderate — start High as a systematic review of randomised trials, −1 risk of bias because most included trials had unclear or high risk in at least one key domain; Not downgraded for inconsistency (I² 29%) or imprecision (RR 0.73, 95% CI 0.63–0.85 on 11,403 participants). Dehiscence: Moderate for the finding of no difference (RR 0.97, 0.82–1.16). Mortality, reoperation, seroma, skin blisters, pain: Low. Haematoma: Very low. The page-level rating of Moderate reflects the primary outcome. No upgrade is available and none is warranted: this is an unrestricted, independent, duplicate-assessed Cochrane review, and the ceiling on its certainty is set by the quality of the trials it pools, not by its own conduct.

Figures: Figures checked

Statistics: recomputed from the paper's own figures: 6 of 6 reproduce.

Norman G, Shi C, Goh EL, Murphy EMA, Reid A, Chiverton L, Stankiewicz M, Dumville JC. Negative pressure wound therapy for surgical wounds healing by primary closure. Cochrane Database Syst Rev. 2022;4(4):CD009261 (Version pub7; supersedes pub5 (2020;5(5):CD009261))
PubMedDOIReviewed 2026-09-18
Case seriesGRADE ⊕◯◯◯ Very low2025Context

The first denominator-based series of NPWT applied directly over an arterial repair

Negative pressure wound therapy for combat-related extremity vascular injuries: clinical experience from the war in Ukraine — Sivash II, Koval BM · Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2025;33(1):188
What it found

69 male active-duty personnel, mean age 33.4 ± 9.3. Mechanism mine-blast 71%, gunshot 23%. Vessels: brachial 33.3%, superficial femoral 23.2%, popliteal 11.5% — the remaining 32% of injured vessels are never enumerated. Combined arterial-venous injury 40%; fracture 42%; primary wound contamination 56.5%. 97 reconstructive procedures across 69 patients (autovenous grafting 43, end-to-end 14, PTFE 4, patch 8, ligation 10, temporary shunt 11, thrombectomy 7) — so the number of patients carrying an interposition graft versus a primary repair under the dressing is not recoverable.

Outcomen/69%Wilson 95% CI
Any complication1927.518.4 to 39.0
Erosion-related bleeding913.07.0 to 23.0
— of which occurred at Role IV45.82.3 to 14.0
Recurrent bleeding34.31.5 to 12.0
Arterial thrombosis68.74.0 to 17.7
Purulent wound complication45.82.3 to 14.0
Secondary amputation22.90.8 to 10.0
In-hospital mortality000 to 5.3
Limb salvage6797.190.0 to 99.2
Primary closure5275.464.0 to 84.0
Split-thickness skin graft1217.410.2 to 28.0
Flap34.31.5 to 12.0

Mean length of stay 29.1 ± 11.2 days, median 26.

Limitations

1. Attribution failure for the headline harm — 5 of 9 bleeds and 5 of 6 thromboses occurred outside the facility where NPWT was documented. 2. No time-to-event data; the bimodal windows are unplotted and untestable on nine events. 3. Internal contradiction in the bleeding counts — "9 cases" with "recurrent in 3 patients (three episodes each)" implies 15 episodes, the text elsewhere says "seven episodes", and Table 2's management list sums to exactly 9. 4. PTFE contradiction — the text says two PTFE grafts were used at reoperation for erosive bleeding at Role IV; Table 2's list of the nine bleeding reoperations contains no PTFE and lists allograft instead. 5. A listed outcome is never reported — number of dressing changes. 6. No prognostic-variable set at all. Ischaemia time, tourniquet duration, time to repair, fasciotomy (the word appears nowhere), injury severity score, shock grade, transfusion, anticoagulation and antibiotic regimen are all absent. The authors state that "Formal injury severity scoring (ISS/NISS) could not be applied" and that "Primary medical records were missing in more than 50% of the cases." 7. No accounting for the 16 excluded patients and no flow diagram. 8. Selection on the exposure — only patients who received NPWT were analysed. 9. No follow-up beyond a median 26-day stay; patency, function and late amputation are unknown. 10. Table 4's citation numbering is systematically wrong — three of six comparator citations point to the wrong paper — and its data are wrong in several places: Geiger is 2008 not 2011, 68 patients not 62, San Diego not Iraq, with 3 amputations in 68 (4.4%) not 5.8%. Peck's cohort was local Iraqi civilians including 12 children, not service members. 11. Discussion overreach. "Safe and effective adjunct" from a single-arm series; "mitigation of erosion-related bleeding" when no mitigation was measured and the paper's own 13% is the second-highest rate in its own comparison table; and "they are cost-effective overall because of reduced hospital days, fewer infections, and lower amputation rates" — no cost data of any kind were collected. 12. No retracted reference — twelve load-bearing citations checked and clean. But Alga is mischaracterised (described as finding no superiority "in smaller wounds"; the trial was not restricted to smaller wounds and closure by day 5 numerically favoured standard treatment) and Dosluoglu is misreported (cited for "a median healing time of 10-12 days"; Dosluoglu reports all wounds healed at a mean of 49 ± 21 days).

Appraisal and reference

CAT: OCEBM 4 · Start Low (single-arm observational series). -1 risk of bias, and the reasons are structural: Selection is on the exposure - only patients who received NPWT were analysed, so the series cannot separate the effect of NPWT from the effect of being judged suitable for it; the 16 screened-but-not-included patients are never characterised and there is no flow diagram; Primary medical records were missing in more than 50% of cases, on the authors' own statement; the authors were the treating surgeons with no blinding and no independent adjudication; and ethics approval was obtained on 26 May 2025, approximately 2.5 years after the last patient was treated, so no prospective governance existed over data capture. -1 further for the absence of any prognostic-variable set: ischaemia time, tourniquet duration, time from injury to repair, FASCIOTOMY (the word appears nowhere in the paper), injury severity score (the authors state 'Formal injury severity scoring (ISS/NISS) could not be applied'), shock grade, transfusion volume, anticoagulation regimen and antibiotic regimen are all ABSENT, so no adjustment is possible and none was attempted; and because 97 reconstructive procedures are reported across 69 patients, the number of patients carrying an interposition graft versus a primary repair versus a patch under the dressing is not recoverable. Net very low. The decisive attribution problem, which is not a GRADE domain but governs how the page may be used: 5 of the 9 erosion bleeds and 5 of the 6 thromboses occurred at role II-III, where NPWT use is undocumented and where NPWT at Role IV was the inclusion criterion. The NPWT-attributable bleeding rate at the facility where the two-layer protocol was applied is therefore 4/69 (5.8%, Wilson 95% CI 2.3 to 14.0), not 13.0%. Separately, the two claimed risk windows of days 7-10 and 18-30 are a NARRATIVE READING of nine events summarised only by a median of 18 and a range of 6 to 29: there is no histogram, no Kaplan-Meier, no swimmer plot and no event table anywhere in the paper, the earliest event at day 6 falls outside both windows, and no event occurred after day 29 although the upper window extends to day 30.

Figures: Figures checked

Sivash II, Koval BM. Negative pressure wound therapy for combat-related extremity vascular injuries: clinical experience from the war in Ukraine. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine. 2025;33(1):188.
PubMedDOIReviewed 2026-08-01
Review / backgroundGRADE ⊕◯◯◯ Very low2021Context

Retained NPWT foam: what to tell patients at consent, and why the true rate is unknown

Retained Negative Pressure Wound Therapy Foams as a Cause of Infection Persistence — Anagnostakos K, Thiery A, Sahan I · Advances in Wound Care (New Rochelle) 2021;10(12):699-710
What it found
  • "the same surgical team should ideally perform all VAC revisions until the end of the therapy."
  • "A count of the inserted foams should be made at each procedure (similar to the standard practice for swabs, needles, and instruments)."
  • "Attempts should be made to use the largest single piece of foam in the wound bed. Whenever possible, the use of more than one piece of foam should be avoided."
  • "If foams have to be trimmed ... the trimming itself should take place away from the wound and the patient to reduce the risk of fragments in the wound."
  • "The precise number of the inserted foams and their localization(s) should be consistently documented in the operative note, so that even if another team should carry out the next revision surgery, all foams could be easily and reliably identified." … "it is the responsibility of the surgical team and not of the electronic device to provide a precise and errorless documentation of all used materials."
  • "In some cases, the foams are so adherent to the surrounding soft tissues that local application of saline or sterile water is recommended to loosen the foam before removal is reattempted."
  • "At foam removal, all dressing materials should be examined for integrity. Should any discrepancy be evident with regard to the number or size of the removed foams, the wound should be further explored to resolve this discrepancy."
  • Take-home: "At the smallest doubt that all foams are fully removed, the wound should be further explored."
Limitations

1. The "up to 10%" claim is not supported (boxed above) and contradicts the review's own body text. 2. Caniano's subgroup attribution is unverifiable — the source reports 2 retained sponges among 51 patients without assigning them. 3. Yusuf's colonisation rate is misreported. The review states "Colonized foams were observed in 54% of cases"; Yusuf reports 65 of 68 foams (97%) with at least one bacterial type and 54% with two or more. The review's own following sentences (43% + 32% + 22% = 97%) contradict its 54%. 4. The German DRG growth figure is wrong — "increased by 369% between 2005 and 2015"; the source reports 349%, from 2005 to 2014. 5. Gawande's n is misstated as 61 cases; the source has 54 cases with 61 retained foreign bodies plus 235 controls, and one of the 54 died. 6. The 1-in-3,000 figure is unsourced within its citation. 7. "All publications, except for one, were case reports" is inaccurate — two of the nine are series. 8. No ethics or consent statement for the two unpublished patients whose radiographs, MRI and intraoperative photographs are published. 9. Discussion overreach. "it could be assumed that there might be a high rate of unrecognized fragmented foams left in situ" appears in the same paragraph as the concession that no rate exists. Scherrer 2016, cited to support foam colonisation, actually concluded that the diagnostic value of foam cultures was poor (sensitivity 58%, specificity 86%) — evidence against foam culture, deployed here as evidence for foam-borne infection. 10. No retracted reference — all nine case sources and twenty further references checked against PubMed and clean. One bibliographic error: Gwan-Nulla is dated 2011 in the reference list and is 2001. 11. Governance. Funding: "The present work did not have any financial support." Disclosure: "No competing financial interests exist." Table 1 lists 30 named commercial NPWT devices from 12 manufacturers, and the review's central recommendation is a direct call on industry to add radiopaque markers — declared alongside no competing interests.

Appraisal and reference

CAT: OCEBM 5 · This is a narrative review of case reports and there is no effect estimate to grade. What can be graded is the INCIDENCE CLAIM, and it does not survive. The abstract states 'initial studies have indicated rates of up to 10% in large collectives being treated by NPWT'. That phrase appears nowhere in the body. The body contains exactly two numbers: Caniano 2005 at 2 of 21 (9.5%) and Dessy 2015 at 11 of 345 (3.2%). Caniano is a paediatric pilonidal subgroup of a 51-child series whose own abstract reports the two retained sponges against the full 51 - 3.9% - without assigning them to that subgroup at all, so the review's attribution is unverifiable from the source. Pooling both denominators gives 13/366 = 3.6%; with Caniano's full denominator, 13/396 = 3.3%. The source fails the abstract's framing on three counts: the cohort is paediatric general and pilonidal surgery, not orthopaedic and not vascular; n = 21 is not a 'large collective', and the review's own body text says the opposite - 'Most identified studies are case reports with no exact statements about the incidence of this complication within a large collective'; and the plural 'initial studies' at that level rests on a single subgroup of a single 2005 retrospective series. The detection claim is assertion plus descriptive tabulation: no bench work, no phantom study, no diagnostic accuracy study and no sensitivity or specificity for any imaging modality appears anywhere; the only supporting text is that six of nine studies used imaging and that in all of them 'the particular imaging method was not indicative of the retained foams but rather of abscess formations or cavities'. No imaging modality is reported to work, and ultrasound is not mentioned once. The authors' own two cases make the point: MRI reported an abscess and the excised objects were a 16 x 4 x 2 cm and an 8 x 4 x 4 cm polyurethane foam. The risk factors are mostly imported OR asserted: emergency or unplanned surgery, unplanned change of procedure and high BMI are derived from a different population entirely - Gawande 2003, a malpractice-claims case-control study of retained sponges and instruments, not NPWT foam (emergency surgery RR 8.8, 2.4-31.9; unplanned change 4.1, 1.4-12.4; BMI per unit 1.1, 1.0-1.2), and no NPWT-specific quantification exists; change of surgical team and absence of standardised documentation are ASSERTED and are not coded variables in any case; the dressing-change dose-response is extrapolated from a single descriptive statistic with no denominator and no comparison group; and the polyurethane-versus-PVA fragmentation claim is bench chemistry, with the review's own words being that PU 'THEORETICALLY has a higher risk of fragmentation' and that 'no study has provided any information about the rate of fragmented foams in clinical practice'.

Figures: Figures checked

Anagnostakos K, Thiery A, Sahan I. Retained Negative Pressure Wound Therapy Foams as a Cause of Infection Persistence. Advances in Wound Care (New Rochelle). 2021;10(12):699-710.
PubMedDOIReviewed 2026-08-01
Case reportNot graded2026Context

The wound that got worse under negative pressure because the disease was not an infection

Postoperative Pyoderma Gangrenosum Mimicking Early Periprosthetic Joint Infection After Total Hip Arthroplasty in a Patient With Hairy Cell Leukemia: A Diagnostic Challenge — Lehnert R, Schneider S, Walker B, Schrednitzki D · Cureus 2026;18(6):e111606
What it found

An 83-year-old woman, elective right total hip arthroplasty, no dermatological history, one abnormal preoperative value: a mild leukocytopenia.

DayEventCRP (mg/L)
0Total hip arthroplasty, uneventful—
2Postoperative CRP peak183
6Erythema at the wound margin128
7Pustules, purulent-haemorrhagic secretion, severe pain disproportionate to the findings160
8First revision — debridement, head and liner exchange, cefuroxime—
10Second revision, cultures and histology taken223
13NPWT applied, ampicillin/sulbactam—
18Biopsy confirms pyoderma gangrenosum; NPWT discontinued151
21Oral prednisolone started once granulation appeared72
54Secondary closure achieved, prosthesis retained4

At both operations the inflammation was confined to skin and subcutaneous fat. Fascia, muscle and the arthroplasty components were macroscopically normal. Cultures gave S. epidermidis in one of four samples after prolonged incubation and C. acnes in one during NPWT after extended incubation, both read as contaminants. The biopsy showed a dense dermal neutrophilic infiltrate with oedema and focal necrosis, no vasculitis, no granulomas and no organisms — a sterile neutrophilic dermatosis.

The withdrawal is recorded in one sentence:

"In light of this diagnosis, the VAC therapy was discontinued to prevent further mechanical trauma and potential exacerbation of the pathergy phenomenon."

And the rule the authors draw from it:

"Repeated debridements, component exchanges, and aggressive negative-pressure wound therapy may paradoxically worsen PG due to pathergy and should be avoided once PG is suspected."

The diagnosis of the skin disease found the systemic one. Bone marrow biopsy showed CD20-positive hairy cell leukaemia, explaining the chronic leukocytopenia. Ten days, two operations and four antibiotic regimens were spent before the first dermatological opinion.

Limitations
  • n = 1, retrospective, unblinded, no comparator, no registration. OCEBM 5. Nothing here is an effect estimate.
  • The VAC episode is undocumented as a technical intervention, so no protocol statement can be derived from it.
  • Co-intervention throughout: two operations, four antibiotic regimens and systemic corticosteroids over 54 days.
  • A miscitation is present and is a finding. The sentence describing the established diagnostic criteria for pyoderma gangrenosum — a major histopathological criterion plus minor criteria including pathergy, exclusion of infection and response to immunosuppression — is supported by reference 10, which is *Kaushik RD et al., "C-reactive protein and hypertension grade in newly detected, treatment naive adults: a case-control study", Int J Drug Deliv Technol 2026;16:537-48. That paper cannot be a source for those criteria, and a reader cannot reach the real ones from this reference list.*
  • Figure 4's sub-captions do not form a consistent sequence. (A) three weeks after the second debridement; (B) seven weeks, progressive granulation; (C) three months after discontinuation of VAC, advanced healing; (D) seven weeks, complete epithelialisation. B and D carry the same interval and describe different stages, with C chronologically between them. The photographic timeline cannot be reconstructed from the captions; the tabular one can, and is the one used here.
  • No dermatosis or rheumatological population is otherwise represented in this library, so this page has no comparator inside this library.
  • Retraction status is unknown and unverifiable here. No PMID is printed, so the publication-type check this library requires cannot be run offline. The PDF carries no retraction or expression-of-concern notice.
  • Funding and conflicts are declared as none for all four authors, in the ICMJE form reproduced in the article.
Appraisal and reference

CAT: OCEBM 5 (single case report) / GRADE not applicable — no effect estimate exists to grade, because a single patient generates no comparison. JBI Critical Appraisal Checklist for Case Reports applied instead, with CARE used as the reporting-completeness check. · GRADE cannot be applied and saying so is the point: there is one patient, no comparator and no estimate, so no certainty rating in an effect can be produced. The value of this paper is not an effect estimate. It is that it names a disease in which negative pressure wound therapy is contraindicated by mechanism, and this library has never named it. Pyoderma gangrenosum is a sterile neutrophilic dermatosis in which minor trauma provokes new and larger lesions — the pathergy phenomenon — so debridement and NPWT do not merely fail to help, they extend the ulcer. The paper's Clinical message states it in terms this library can adopt: repeated debridements, component exchanges and aggressive negative-pressure wound therapy 'may paradoxically worsen PG due to pathergy and should be avoided once PG is suspected', and the operative note records the decision as discontinuation 'to prevent further mechanical trauma and potential exacerbation of the pathergy phenomenon'. Every other harm held in this library is the therapy injuring a wound that would otherwise heal — Bleeding, vessel erosion, retained foam, adhesive and port injury. This one is the therapy feeding the disease. Two limits travel with it and must be stated wherever it is cited. First, the harm is inferred and not measured: the report's own CRP series FELL from 223 mg/L on day 10, before NPWT, to 151 mg/L on day 18 at the end of it, and no wound measurement, lesion count or pain score is reported for the interval the therapy was running; the authors write only that surgery and VAC 'likely contributed'. Second, withdrawal and corticosteroids are three days apart in a disease that responds to corticosteroids, so recovery is attributed to two interventions changed together. The case is therefore decisive as a diagnostic and stopping rule and weak as a demonstration of harm, and the contraindication rests on the disease mechanism rather than on this patient's course. Downgraded further for reporting: the NPWT episode carries no pressure setting, no foam type, no interface, no exchange interval and no wound dimensions, so nothing in it can reach a protocol page.

Figures: Figures checked

Lehnert R, Schneider S, Walker B, Schrednitzki D. Postoperative Pyoderma Gangrenosum Mimicking Early Periprosthetic Joint Infection After Total Hip Arthroplasty in a Patient With Hairy Cell Leukemia: A Diagnostic Challenge. Cureus. 2026;18(6):e111606 (Received for review 8 June 2026, review ended 24 June 2026, published 27 June 2026. All authors declare that no financial support was received for the submitted work and that they have no financial relationships with any organisation with an interest in it. Informed consent for treatment and open-access publication was obtained or waived)
PubMedDOIReviewed 2026-08-02
Meta-analysis / SRGRADE ⊕⊕◯◯ Low2025Challenges NPWT

Cochrane review of preventing aortic graft infection; it contains only one NPWT trial

Prevention of infection in aortic or aortoiliac peripheral arterial reconstruction (Cochrane Review) — Cristino MAB, Nakano LCU, Vasconcelos V, Correia RM, Flumignan RLG · Cochrane Database of Systematic Reviews 2025, Issue 4. Art. No.: CD015192
What it found

Comparisons 14 (short-term) and 15 (long-term). Single study throughout, so I-squared is undefined in every analysis and every forest plot prints "Heterogeneity: Not applicable". No sensitivity analysis, no subgroup analysis.

OutcomeNPWTStandard dressingEffectGRADE
Graft infection, short-term0/1830/194Not estimableLow
Surgical site infection (short- and long-term, identical data)5/183 (2.73%)11/194 (5.67%)RR 0.48 (95% CI 0.17 to 1.36), Z = 1.38, p = 0.17Low
Amputation0/1830/194not estimableLow
Re-intervention, long-term4/1836/194RR 0.71 (0.20 to 2.46), p = 0.59Low
Adverse events, long-term12/183 (6.6%)0/194 (0%)RR 26.49 (1.58 to 444.28), p = 0.02Very low
All-cause mortality——not measured—
Pain——not measured (folded into the adverse-event composite)—
Arterial reconstruction failure——no data—

Absolute effect on SSI: 57 per 1,000 falling to 27 per 1,000 (10 to 77); risk difference 2.94 percentage points; NNT about 34 per incision. Adverse events were defined as intolerance of the unit or tubing, pain or discomfort, and disturbance from pump noise — NNH about 16 incisions.

Certainty was downgraded for risk of bias (blinding of participants, personnel and outcome assessment — nurses and physicians were unblinded during the inpatient period when some infections were diagnosed) and for imprecision (few events, wide intervals). It was never downgraded for inconsistency, because with one study there is nothing to be inconsistent with.

Limitations
  • Most studies did not report the time point of outcome measurement, so the review had to treat maximum follow-up as the measurement point.
  • SSI diagnostic criteria were not uniform — six used Szilagyi, five used their own, one used CDC, seven described none.
  • Four included studies had mixed populations with unextractable subgroup data and were retained whole.
  • Many trials with under 50% of participants in the subgroup were excluded because authors did not supply raw data despite being contacted.
  • No publication-bias assessment anywhere — fewer than 10 studies in every comparison.
  • Unit-of-analysis departure from protocol in the two trials analysing groins rather than patients. The NPWT pooling is a naive unpaired 2x2 across 377 incisions from 209 patients; the trial's own paired analysis returned a combined p of 0.49.
  • Planned subgroup analyses (prophylaxis start, age, BMI, surgery type, aneurysm versus PAD) were largely infeasible.
Appraisal and reference

CAT: OCEBM 1 · This is the certainty the REVIEW assigns, and it is reproduced here rather than re-derived, because the review's GRADE process is documented and its reasons are stated. For the NPWT comparison the certainty is Low throughout, downgraded on two domains only: Risk of bias (Svensson-Bjork 2022 is High RISK for blinding of participants and personnel and High RISK for blinding of outcome assessment - nurses and physicians were unblinded during the postoperative inpatient period, which is when some infections were diagnosed) and IMPRECISION (few events, wide confidence intervals; for amputation the review notes explicitly that 'no events were reported in either group, and the sample size calculation did not account for the low incidence of postoperative amputation'). It is never downgraded for inconsistency, and the reason is decisive: There is only one trial, so I-squared is undefined in every analysis and every forest plot prints 'Heterogeneity: Not applicable'. For the device-related adverse-event outcome the certainty is Very low, downgraded for risk of bias and for imprecision on 12 events against zero. Two further considerations this library should carry but which do not change the review's own rating: the pooling is a NAIVE UNPAIRED 2x2 across 377 incisions from 209 patients, ignoring the paired structure of the 336 bilateral incisions, which the review acknowledges only as a departure from its protocol unit of analysis - the trial's own paired analysis returned a combined p of 0.49; and the single included trial declares research funds from Smith & Nephew, which also provided 100 PICO dressings, which is worth recording because it makes a null a stronger null rather than a weaker one.

Figures: Figures checked

Cristino MAB, Nakano LCU, Vasconcelos V, Correia RM, Flumignan RLG. Prevention of infection in aortic or aortoiliac peripheral arterial reconstruction. Cochrane Database of Systematic Reviews. 2025;(4):CD015192.
PubMedDOIReviewed 2026-08-01

How the evidence points

HighMod.LowV. lowNone
Supports00305
Challenges01214

Sources tagged to this page, by direction and GRADE certainty (Mod. = Moderate, V. low = Very low, None = not graded). Context sources (no comparison, or a comparison that does not test NPWT) and retracted papers are not counted. How direction is decided.

All 80 sources

More filters
Loading 80 sources…